Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma
AbstractAsthma is one of the most important medical and social problems of our time due to the prevalence and the complexity of its treatment. Chronic inflammation that is characteristic of asthma is accompanied by bronchial obstruction, which involves various lipid mediators produced from n-6 and n-3 polyunsaturated fatty acids (PUFAs). The review is devoted to modern ideas about the PUFA metabolites—eicosanoids (leukotrienes, prostaglandins, thromboxanes) and specialized pro-resolving lipid mediators (SPMs) maresins, lipoxins, resolvins, protectins. The latest advances in clinical lipidomics for identifying and disclosing the mechanism of synthesis and the biological action of SPMs have been given. The current views on the peculiarities of the inflammatory reaction in asthma and the role of highly specialized metabolites of arachidonic, eicosapentaenoic and docosahexaenoic acids in this process have been described. The possibility of using SPMs as therapeutic agents aimed at controlling the resolution of inflammation in asthma is discussed. View Full-Text
Share & Cite This Article
Kytikova, O.; Novgorodtseva, T.; Denisenko, Y.; Antonyuk, M.; Gvozdenko, T. Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma. Medicina 2019, 55, 284.
Kytikova O, Novgorodtseva T, Denisenko Y, Antonyuk M, Gvozdenko T. Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma. Medicina. 2019; 55(6):284.Chicago/Turabian Style
Kytikova, Oxana; Novgorodtseva, Tatyana; Denisenko, Yulia; Antonyuk, Marina; Gvozdenko, Tatyana. 2019. "Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma." Medicina 55, no. 6: 284.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.